Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer
化疗药导出包含编码肿瘤 suppressor 蛋白质治疗三元组否定的乳癌的 mRNA 的 nanoparticles作者机构：Division of Pharmaceutics & Pharmaceutical Chemistry College of Pharmacy The Ohio State University Columbus OH 43210 USA Present address: State Key Laboratory of Fine Chemicals Dalian University of Technology Dalian 116024 China College of Pharmacy The Ohio State University Columbus OH 43210 USA Center for Electron Microscopy and Analysis The Ohio State University Columbus OH 43212 USA Department of Materials Science and Engineering The Ohio State University Columbus OH 43210 USA Department of Biomedical Engineering The Ohio State University Columbus OH 43210 USA The Center for Clinical and Translational Science The Ohio State University Columbus OH 43210 USA The Comprehensive Cancer Center The Ohio State University Columbus OH 43210 USA Dorothy M. Davis Heart & Lung Research Institute The Ohio State University Columbus OH 43210 USA Department of Radiation Oncology The Ohio State University Columbus OH 43210 USA
出 版 物：《Nano Research》 (纳米研究（英文版）)
年 卷 期：2019年第12卷第4期
页 面：855-861页
核心收录：
基 金：supported by the Maximizing Investigators’ Research Award the National Institute of General Medical Sciences
主 题：clitaxel amino lipid derived nano particles mRNA therapeutics combi nation therapy triple- negative breast cancer
摘 要：Triple-negative breast cancer(TNBC)is one type of the most aggressive breast can cers with poor prog no *** is of great urgency to develop new therapeutics for treati ng *** on curre nt treatment guideline and genetic informatio n of TNBC,a combi nation al therapy platform in tegrati ng chemotherapy drugs and mRNA encoding tumor suppressor proteins may become an efficacious *** this study,we developed paclitaxel amino lipid(PAL)derived nanoparticles(NPs)to incorporate both chemotherapy drugs and P53 *** PAL P53 mRNA NPs showed superior properties compared to Abraxane? and Lipusu? used in the clinic including high paclitaxel loading capacity(24 wt.%,calculated by paclitaxel in PAL),PAL encapsulation efficiency(94.7%±6.8%)and mRNA encapsulation efficiency(88.7%±0.7%).Meanwhile,these NPs displayed synergetic cytotoxicity of paclitaxel and P53 mRNA in cultured TNBC *** importantly,we demonstrated in vivo anti-tumor efficacy of PAL P53 mRNA NPs in an orthotopic TNBC mouse ***,these chemotherapy drugs derived mRNA NPs provide a new platform to integrate chemotherapy and personalized medicine using tumor genetic information,and therefore represent a promising approach for TNBC treatment.
维普期刊数据库